X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs DISHMAN PHARMA - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES DISHMAN PHARMA PIRAMAL ENTERPRISES/
DISHMAN PHARMA
 
P/E (TTM) x 36.6 25.1 146.0% View Chart
P/BV x 3.0 3.3 91.0% View Chart
Dividend Yield % 0.8 0.7 120.3%  

Financials

 PIRAMAL ENTERPRISES   DISHMAN PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-17
DISHMAN PHARMA
Mar-16
PIRAMAL ENTERPRISES/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs2,095374 559.6%   
Low Rs1,025129 795.2%   
Sales per share (Unadj.) Rs492.8197.8 249.1%  
Earnings per share (Unadj.) Rs72.621.2 342.2%  
Cash flow per share (Unadj.) Rs94.734.7 272.7%  
Dividends per share (Unadj.) Rs21.002.00 1,050.0%  
Dividend yield (eoy) %1.30.8 169.4%  
Book value per share (Unadj.) Rs862.5179.9 479.4%  
Shares outstanding (eoy) m172.5680.69 213.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.21.3 248.8%   
Avg P/E ratio x21.511.9 181.2%  
P/CF ratio (eoy) x16.57.2 227.3%  
Price / Book Value ratio x1.81.4 129.3%  
Dividend payout %28.99.4 306.9%   
Avg Mkt Cap Rs m269,19420,306 1,325.7%   
No. of employees `0004.00.8 484.1%   
Total wages/salary Rs m17,9395,355 335.0%   
Avg. sales/employee Rs Th21,190.319,252.7 110.1%   
Avg. wages/employee Rs Th4,470.16,459.5 69.2%   
Avg. net profit/employee Rs Th3,120.02,064.1 151.2%   
INCOME DATA
Net Sales Rs m85,03715,961 532.8%  
Other income Rs m2,338265 880.7%   
Total revenues Rs m87,37416,226 538.5%   
Gross profit Rs m34,9914,103 852.8%  
Depreciation Rs m3,8171,091 350.0%   
Interest Rs m20,310944 2,150.6%   
Profit before tax Rs m13,2022,334 565.7%   
Minority Interest Rs m1,6990-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m-1000-   
Tax Rs m2,281624 365.8%   
Profit after tax Rs m12,5201,711 731.7%  
Gross profit margin %41.125.7 160.1%  
Effective tax rate %17.326.7 64.7%   
Net profit margin %14.710.7 137.3%  
BALANCE SHEET DATA
Current assets Rs m87,59011,018 795.0%   
Current liabilities Rs m185,5789,517 1,950.0%   
Net working cap to sales %-115.29.4 -1,225.4%  
Current ratio x0.51.2 40.8%  
Inventory Days Days31110 28.1%  
Debtors Days Days4835 136.5%  
Net fixed assets Rs m108,52316,304 665.6%   
Share capital Rs m345161 213.8%   
"Free" reserves Rs m148,48112,907 1,150.4%   
Net worth Rs m148,82614,516 1,025.3%   
Long term debt Rs m144,9574,189 3,460.1%   
Total assets Rs m482,39429,805 1,618.5%  
Interest coverage x1.73.5 47.5%   
Debt to equity ratio x1.00.3 337.5%  
Sales to assets ratio x0.20.5 32.9%   
Return on assets %6.88.9 76.4%  
Return on equity %8.411.8 71.4%  
Return on capital %12.017.5 68.2%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m15,0014,952 303.0%   
Fx outflow Rs m5,150697 739.1%   
Net fx Rs m9,8514,255 231.5%   
CASH FLOW
From Operations Rs m-100,3932,786 -3,603.0%  
From Investments Rs m-24,202-1,529 1,583.0%  
From Financial Activity Rs m135,705-941 -14,419.8%  
Net Cashflow Rs m11,110316 3,511.3%  

Share Holding

Indian Promoters % 52.9 61.4 86.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 3.7 108.1%  
FIIs % 26.6 12.7 209.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 22.1 74.7%  
Shareholders   93,274 46,261 201.6%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   AUROBINDO PHARMA  MERCK LTD  GSK PHARMA  FULFORD INDIA  ORCHID PHARMA LTD  

Compare PIRAMAL ENTERPRISES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Feb 16, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES - TTK HEALTHCARE COMPARISON

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS